FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

8 August 2014

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals (Nasdaq: TKMR) revealed yesterday that the US Food and Drug Administration has verbally confirmed it has modified the full clinical hold placed on its TKM-Ebola Investigational New Drug application to a partial clinical hold.

Tekmira’s shares rose 8% to $15.422 in extended trading yesterday at 6:58 pm New York time after closing at $14.27, Bloomberg reported.

This action, which comes in the wake of the increasing death toll in several African countries and arguments that the FDA should take action on moving forward possible treatments for the devastating Ebola disease, enables the potential use of TKM-Ebola in individuals infected with Ebola virus, the company noted. At present, there are no approved treatments for Ebola disease. The virus has killed 932 people of more than 1,700 infected, and the disease continues to spread.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK